PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE

100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:


Scientific evidence for clinical utility.

By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrintยฎ and BluePrintยฎ test suite.

Evidence

Successful Unconventional Precision Treatment of Inflammatory Hormone Receptor-Positive Breast Cancer Guided by Molecular Profiling

Publication: npj Precision Oncology | (2025) 9:63 Authors: Jailan Elayoubi , Yu Zong & Erich J. Schwartz Title: Successful unconventional precision treatment of inflammatory hormone receptor-positive breast cancer guided by molecular profiling Abstract: We present a unique case of locally advanced, inflammatory hormone receptor (HR) positive, human epidermal growth Read More

Neoadjuvant HER2-Targeted Therapy Response by BluePrint Gene Expression-Based Molecular Subtyping in Patients with HER2+ Early-Stage Breast Cancer from FLEX

Publication: 19th SGBCC 2025-P201 Authors: Laila Samiian, Adam Brufsky, Sahra Uygun, Isha Kapoor, Victoria Poillucci, Joyce Oโ€™Shaughnessy, William Audeh Title: Neoadjuvant HER2-Targeted Therapy Response by BluePrintยฎ Gene Expression-Based Molecular Subtyping in patients with HER2+ Early-Stage Breast Cancer from FLEX Introduction: โ€ข Clinical HER2+ (cHER2+) early-stage breast cancer (EBC) accounts Read More

Genomic risk classification and whole transcriptome analysis of HR+/HER2- Post-partum breast cancers โ€“ A FLEX sub study

Publication: ESMO Breast 2024 Authors:ย Virginia F. Borges1, Elena Shagisultanova1, Joyce O'Shaughnessy2, Adam Brufsky3, Reshma L. Mahtani4, Kent Hoskins5, Hannah Linden6, Nina D'Abreo7, Sahra Uygun8, Lavanya Samraj8, William Audeh8 University of Colorado Anschutz Medical Campus, Aurora CO 2. Baylor University Medical Center, Dallas, TX 3. University of Pittsburgh Medical Center Read More

Neoadjuvant Chemotherapy for T3 Tumors in the Era of Precision Medicineโ€”Biology Is Still King

Publication: International Journal of Molecular Sciences 2025, 26, 491 Authors: Rakhshanda Layeequr Rahman, Alfredo Santillan, Mehran Habibi, Peter Beitsch, Pat Whitworth, Harshini Ramaswamy, Nicole Chmielewski-Stivers, Andrea Menicucci, William Audeh, and Joyce Oโ€™Shaughnessy Title: Neoadjuvant Chemotherapy for T3 Tumors in the Era of Precision Medicineโ€”Biology Is Still King Abtract: Clinical Read More

FLEX: A Real-World Evidence, Full Transcriptome Study in 30,000 Patients With Early-Stage Breast Cancer

Source: San Antonio Breast Cancer Symposiumยฎ Authors: Robert Maganini, Ellis Levine, Kent Hoskins, Sarah Thayer, Alfredo Santillan, Sung HoLee, Eduardo Dias, Regina Hampton, Eric Brow Title: FLEX: A Real-World Evidence, Full Transcriptome Study in 30,000 Patients With Early-Stage Breast Cancer Background: The advent of subtype-specific treatments, particularly hormone therapies Read More

MammaPrint and BluePrint Predict Pathological Response to Neoadjuvant Chemotherapy in Patients With HR+HER2- Early-Stage Breast Cancer Enrolled in FLEX

Source: San Antonio Breast Cancer Symposiumยฎ Authors: Joyce Oโ€™Shaughnessy, Priyanka Sharma, Cynthia R C Osborne, Gregory Vidal, Pond Remsen Kelemen, Suzanne Hoekstra, Harshini Ramaswamy, Nicole Stivers, Andrea Menicucci, William Audeh, FLEX Investigatorsโ€™ Group Title: MammaPrintยฎ and BluePrintยฎ Predict Pathological Response to Neoadjuvant Chemotherapy in Patients With HR+HER2- Early-Stage Breast Read More